Inhibition of the proliferation of malignant hematopoietic cells by Ki11502
| Cell line . | Gene alteration . | IC50, μM* . |
|---|---|---|
| Eosinophilic leukemia: EOL-1 | FIP1L1/PDGFRα | 0.0002 |
| Biphenotypic leukemia: MV4-11 | FLT3-ITD | 0.5 |
| Myeloid leukemia | ||
| MOLM13 | FLT3-ITD | 0.6 |
| Kasumi-1 | c-KIT (Asn822Lys) | 1 |
| U937 | 2 | |
| THP-1 | — | Not achieved |
| HL-60 | — | Not achieved |
| Kcl-22 | Bcr/Abl | 5 |
| K562 | Bcr/Abl | 5 |
| Lymphoblastic leukemia | ||
| PALL-1 | Bcr/Abl | 2 |
| PALL-2 | Bcr/Abl | 3 |
| BALL-2 | — | Not achieved |
| Jurkat | — | Not achieved |
| Multiple myeloma: U266 | — | Not achieved |
| Adult T-cell leukemia | ||
| MT-1 | — | Not achieved |
| MT-2 | — | Not achieved |
| HUT102 | — | Not achieved |
| Cell line . | Gene alteration . | IC50, μM* . |
|---|---|---|
| Eosinophilic leukemia: EOL-1 | FIP1L1/PDGFRα | 0.0002 |
| Biphenotypic leukemia: MV4-11 | FLT3-ITD | 0.5 |
| Myeloid leukemia | ||
| MOLM13 | FLT3-ITD | 0.6 |
| Kasumi-1 | c-KIT (Asn822Lys) | 1 |
| U937 | 2 | |
| THP-1 | — | Not achieved |
| HL-60 | — | Not achieved |
| Kcl-22 | Bcr/Abl | 5 |
| K562 | Bcr/Abl | 5 |
| Lymphoblastic leukemia | ||
| PALL-1 | Bcr/Abl | 2 |
| PALL-2 | Bcr/Abl | 3 |
| BALL-2 | — | Not achieved |
| Jurkat | — | Not achieved |
| Multiple myeloma: U266 | — | Not achieved |
| Adult T-cell leukemia | ||
| MT-1 | — | Not achieved |
| MT-2 | — | Not achieved |
| HUT102 | — | Not achieved |
— indicates not applicable.
Concentration of Ki11502 that induced 50% growth inhibition (IC50) was calculated from dose-response curves.